Trelegy Ellipta is a maintenance treatment for patients with asthma and COPD. "The FDA's acceptance of our ANDA filing for ...

GlaxoSmithKline’s latest earnings call struck an upbeat tone, with management emphasizing broad‑based momentum in specialty medicines, vaccines and late‑stage R&D, even as legacy general medicines and ...

YUPELRI® Collaboration Revenue increased 15% year-over-year1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as ...

Earnings call GSK delivered a strong Q1 2026 with sales up 5% YoY to over GBP 7.6 billion, driven by Specialty Medicines (+14%) and record Shingrix sales (+20%). Core operating profit rose 10%, EPS ...

Strong first-quarter results under new GSK CEO Luke Miels on Wednesday failed to impress investors, who raised concerns ‌that the British drugmaker's performance was enhanced by one-off factors, ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

GSK (GSK) reported better-than-expected financials for Q1 2026 on Wednesday as sales from its HIV and cancer medicines offset a sales decline for its general medicines, including its respiratory ...

In GSK’s first quarter under Luke Miels as CEO, the company’s flagship shingles vaccine, Shingrix, set a new quarterly sales record, while its closely watched asthma launch, Exdensur, showed “early ...